Distinct roles for CD28 and cytotoxic T lymphocyte-associated molecule-4 receptors during T cell activation?
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
C Ytotoxic T lymphocyte-assodated molecule-4 (CTLA-4) is a lymphocyte cell surface receptor originally discovered in a search for molecules having a role in T cell cytotoxicity (1). This molecule is a member of the immunoglobulin superfamily and is homologous to another T cell surface receptor, CD28. Both CD28 and CTLA-4 bind the same counter-receptors, members of the B7 family on APCs. While the role of CD28 during T cell responses to antigen has been well studied, much less is known about the role of CTLA-4. Recent studies on the function of this molecule have been controversial and have yielded seemingly conflicting results. In this issue, a new study (2) provides further evidence on the function of this molecule and lends support to growing evidence that CTLA-4 is a receptor having unique function during an immune response. What follows in this article is an account of the development of this story, an analysis of the significance of the new data, and a discussion of potential fruitful areas of future research on CTLA-4. Role of B7 Molecules in T Cell Costimulation. The interactions of T lymphocytes with APC are key to the generation of an immune response to foreign pathogens, transplanted organs, or to self tissue during autoimmune disease. The specificity of these T cell-APC interactions is provided by the recognition of antigenic peptide-MHC complexes by clonotypic TCR. However, TCR engagement alone generally does not lead to full T cell activation, but may instead lead to T cell clonal anergy. A successful immune response requires additional interactions between the T cell and the APC. These costimulatory interactions thus determine the outcome of TCR engagement, i.e., whether this engagement activates or inactivates subsequent immune responses (3). While the molecular nature of these costimulatory interactions is not fully understood, it is now clear that a key T cell costimulatory signal is provided by interaction of CD28 receptors on T cells with B7 counter-receptors on APC (4). Engagement of the CD28 receptor by B7 molecules triggers a signaling pathway that regulates T cell cytokine production, particularly I1,-2 (4). Two B7 molecules are known, B7-1 (CD80) and B70/B7-2 (CD86), each of which binds CD28 with similar avidity and elicits similar functional effects (5). CTLA-4. CTLA-4 is a second high avidity receptor for B7 molecules that was cloned from a subtracted cytolytic T cell cDNA library (1, 6). CTLA-4 transcripts were detected in activated lymphocytes and were coinduced with T cell cytoxicity. Human and mouse genes encoding CTLA-4 map to the same chromosomal band as CD28 (7, 8), and human CTLA-4 and CD28 have been linked at the molecular level on a yeast artificial chromosome clone (9). Recombinant soluble CTLA-4 binds CD80 and CD86 with higher avidity than recombinant soluble CD28 (5, 10). Although originally identified as a cytolytic T cell-associated molecule, CTLA-4 transcripts have been detected in both CD4 + and CD8 + T cell clones (11). Cell surface expression of CTLA-4 on activated T cells has been detected using specific mAbs. In human T cells (12), CTLA-4 is expressed equally on CD4 + and CD8 + T subsets of activated T cells, whereas with murine cells, CTLA-4 expression is higher on the CD8 + subset (13). Expression of CTLA-4 is highly activation dependent; CTLA-4 is not detected on resting cells but is induced during T cell activation (1, 11-13). Expression is regulated in part by levels of mRNA (1, 11). With activated human T cells, maximal CTLA-4 protein expression was "~2-3% of CD28 (12). CTLA-4 is therefore a high avidity, low abundance receptor for B7 molecules. Functions of CTLA-4 during T Cell Activation. Relatively little is known of the role of CTLA-4 during T cell activation, and the few experiments reported are largely contradictory. Complete conservation was noted in the amino acid sequences of the cytoplasmic tails of murine and human homologues of CTLA-4 (14). Since the cytoplasmic tail of CTLA-4 presumably mediates signal transduction, this sequence conservation suggested that CTLA-4 has an important conserved signaling function. The cytoplasmic tails of CTLA-4 and CD28 show more limited sequence homology (7), so it was therefore difficult to predict from sequence comparisons alone whether CTLA-4 would have similar or different functions than CD28. Initial experiments (12) showed that combinations of CTLA-4 mAb and anti-CD28 mAb or Fab fragments were synergistic in blocking adhesion of activated CD4 + lymphocytes to CDS0-transfected C H O cells, and in blocking T cell proliferation during a mixed lymphocyte reaction (MLR). Anti-CTLA-4 mAb had weak costimulatory activity together with anti-TCR mAb on previously primed CD4 § T cells, but the effects were less than those observed with anti-CD28 mAb plus anti-TCR mAb. Combinations of suboptimal amounts of anti-TCR mAb, anti-CD28 mAb plus antiCTLA-4 mAb were synergistic in their costimulatory ability (12). Another study from this group (15) extended the original findings and showed that the cooperative costimulatory effects of anti-CTLA-4 and anti-CD28 mAbs were greatest at low concentrations of anti-CD28 mAb (and, hence, low occupancy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Self-citationCTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685
Self-citationSchwartz, R. H. (1992) · Cell · doi:10.1016/s0092-8674(05)80055-8 · Cited by 1,293 · cited 3×
“on APC Figure 1.”
InfluentialLanier, L. L., O'Fallon, S., Somoza, C., Phillips, J. H., Linsley, P. S., Okumura, K., Ito, D., & Azuma, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.1.97 · Cited by 480
Self-citation
Cited by
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
CD28 and CTLA-4 coreceptor expression and signal transduction
Rudd, C. E., Taylor, A., & Schneider, H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00770.x · Cited by 898
“Antibody cross-linking is also inhibitory (8, 21, 22), although it is unclear whether there is a straightforward connection between these two sets of observations.”
BackgroundInduction of Peripheral T Cell Tolerance In Vivo Requires CTLA-4 Engagement
Perez, V. L., Van Parijs, L., Biuckians, A., Zheng, X. X., Strom, T. B., & Abbas, A. K. (1997) · Immunity · doi:10.1016/s1074-7613(00)80284-8 · Cited by 716
The Emerging Role of CTLA-4 as an Immune Attenuator
Thompson, C. B., & Allison, J. P. (1997) · Immunity · doi:10.1016/s1074-7613(00)80366-0 · Cited by 634
CD80 (B7-1) Binds Both CD28 and CTLA-4 with a Low Affinity and Very Fast Kinetics
van der Merwe, P. A., Bodian, D. L., Daenke, S., Linsley, P., & Davis, S. J. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.3.393 · Cited by 551
Self-citation
Metadata
- Authors
- Linsley, P. S.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1995-08-01
- Volume
- 182
- Issue
- 2
- Pages
- 289-292
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2084544247
- Cited by
- 104
- References
- 4
- FWCI
- 6.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.